Bronchopullmonary disease is now the leading cause of morbidity and mortality among patients with cystic fibrosis (CF) (28) . In 60 to 90% of CF patients, chronic and progressive bronchitis is associated with persistent isolation of Pseudomonas aeruginosa from sputum cultures (4, 24, 25, 28) . The majority of these Pseudomonas isolates are distinctive for their production of a copious extracellular polysaccharide material, which has been characterized as an alginic acid (14) . These so-called "mucoid" Pseudomonas strains are easily identifiable by colonial characteristics and require no specialized media for primary isolation or identification (5, 6, 27) . Although mucoid strains account for only 0.8 to 2.1% of clinical Pseudomonas isolates in a general population (5) , up to 80% of all Pseudomonas isolates from CF patients have mucoid characteristics (4, 24, 27) .
Once the CF patient harbors mucoid ?seudomonas in the lungs, it is virtually impossible to eliminate it with therapy (5, 11, 27) . There has been recent speculation that mucoid coating of Pseudomonas may offer a survival advantage in the CF respiratory tract by protecting the bacteria from phagocytic cells, antibodies, and even antibiotics (9, 11, 13) . Although several in vitro studies have suggested that mucoid coating of Pseudomonas may be antiphagocytic (1, 26) , this has not been confirmed with in vivo studies. It has been well established that phagocytic cells are the predominant effectors of bactericidal activity in the lungs (8, 29) , and a guinea pig model of experimental P. aeruginosa pneumonia has recently been described in which studies of intrapulmonary phagocytic cell activity for Pseudomonas can be carried out (18) (19) (20) . Factors which might adversely affect normal pulmonary alveolar macrophage or polymorphonuclear leukocyte functions can be detected in this model by decreased clearance of Pseudomonas in the lungs (18, 20) . In Experimental model of lung infection. The guinea pig model of P. aeruginosa pneumonia used in these studies has been previously described (19) . Briefly, 400-g guinea pigs were anesthetized with intraperitoneal pentobarbital, and the trachea was surgically exposed. A 0.5-ml portion of Pseudomonas, suspended in isotonic saline, was then directly instilled into the lower respiratory tract via the trachea. The neck was sutured, and animals were positioned upright until awake. It has been shown in this model that survival from infection and efficiency of Pseudomonas killing in the lungs are influenced by the size and strain of inocula (19, 20, 22) , prior vaccination (19, 22) , prior immunosuppression (18, 20) , or antibiotic treatment (23) . Thus rence and time of any deaths from experimental pneumonia were also noted. After experimental lung infection, groups of guinea pigs were electively sacrificed with intraperitoneal pentobarbital at timed intervals, lungs were removed aseptically, and both the quantity and colonial morphology of viable Pseudomonas in the right lung were determined as previously described (19, 20) . Quantities of viable Pseudomonas were expressed as CFU x 103 per milliliter of lung homogenate, and differences among study groups were analyzed by the two-tailed Student t-test. In selected experiments, left lungs were perfused and fixed with 10% Formalin and prepared for histopathological examination, as described (19, 20) .
In further studies, groups of guinea pigs were prevaccinated with a heptavalent lipopolysaccharide Pseudomonas vaccine (Pseudogen; Parke, Davis & Co., Detroit, Mich.) (10) and evaluated for the potential of mucoid coating to decrease the in vivo efficiency of opsonic antibodies in the lungs. As in previous studies (19) , a 2-week-long series of six injections (50 ,ug of lipopolysaccharide antigen per kg [body weight] per injection) was used, and serum passive hemagglutinating antibody titers were determined. Groups of guinea pigs vaccinated in this manner were challenged with mucoid or nonmucoid Pseudomonas strain 1 (Fisher type 6), and intrapulmonary killing was compared. Nonvaccinated controls were infected and studied simultaneously.
Finally, it has recently been shown that tobramycin sulfate (Nebcin; Eli Lilly & Co., Indianapolis, Ind.) treatment of experimental Pseudomonas pneumonia in guinea pigs enhances intrapulmonary killing of Pseudomonas (23) . To study the potential for mucoid coating to inhibit the in vivo effectiveness of tobramycin, groups of guinea pigs were infected with mucoid or nonmucoid Pseudomonas and treated with doses of tobramycin sulfate known to produce effective levels in guinea pigs (1.7 mg per kg [body weight] every 8 h) (23) , and intrapulmonary killing was compared among study groups. Again, a group of nontreated controls was also infected and studied simultaneously.
RESULTS
Characteristics of Pseudomonas challenge strains. Both Pseudomonas strains used in this study were Fisher type 6, and each was sensitive to gentamicin, tobramycin, amikacin, carbenicillin, ticarcillin, and polymyxin B. Results of serotyping and disk sensitivities did not vary between mucoid and nonmucoid revertant forms. Thus, except for colonial morphology, the mucoid and nonmucoid forms of each strain appeared identical.
Accurate comparisons of pulmonary clearance rates of mucoid and nonmucoid Pseudomonas depended upon delivery of equivalent inocula to the lungs. To ensure that turbidity from exopolysaccharides in suspensions would not cause artifacts in optical density readings, and to prevent inaccurate CFU determinations due to the described tendency for mucoid Pseudomonas to agglutinate into microcolonies (13) , organisms were washed and blended before challenge.
With these precautions, the use of optical densities to provide equivalent inocula for the mucoid versus nonmucoid Pseudomonas challenges was reliable. A total of 15 separate comparative challenges were carried out for strain 1. The mean inoculum for the mucoid groups was 2.27 x 10' CFU (range, 1.4 to 3.3), and for nonmucoid groups the mean was 1.79 x 108 CFU (range, 1.4 to 2.6). These differences were not statistically significant. Likewise, among five separate challenge experiments using strain 3, the mean inoculum for mucoid groups was 1.5 x 108 CFU (range, 0.6 to 2.3), and for nonmucoid groups it was 1.1 x 108 CFU (range, 0.6 to 1.3). Again, differences were not significant. Thus, differences in quantities of viable Pseudomonas cultured from the lungs among the study groups should reflect differences in host killing rather than in inoculumx sizes.
Persistence of Pseudomonas in the lungs. Experimentally infected guinea pig lungs were monitored for the persistence of mucoid and nonmucoid Pseudomonas to determine the length of time necessary for the host to totally eliminate these organisms from the lungs. Accordingly, pairs of guinea pigs infected with strain 1 mucoid and nonmucoid Pseudomonas were sacrificed daily from 1 to 7 days after infection. Pseudomonas was isolated on blood agar plates from infected lungs of both groups for the first 3 days after infection, with the mucoid morphological strain being consistently cultured from animals having received this formn of the challenge bacteria. The mucoid coating potential, therefore, appeared to be preserved in guinea pig lungs. Pseudomonas was not recovered from lungs infected with mucoid strains after the first 72 h of infection; however, occasional nonmucoid Pseudomonas colonies were isolated from the nonmucoid-infected animals up to 6 days after infection. Thus, mucoid coating did not appear to favor prolonged persistence in guinea pig lungs.
Survival and histopathology. difference between mucoid and nonmucoid groups in degree of lung inflammation or lung tissue damage, using previously described criteria (19, 20) . Pulmonary clearance. Table 2 compares the quantities of viable P. aeruginosa retrieved from the lungs of infected animals. Although more mucoid organisms of strain 1 were present 6 h after infection, this difference was not statistically significant. Similarly, numbers of mucoid and nonmucoid strain 1 Pseudomonas isolated 24 and 48 h after infection did not differ significantly. To ensure that strain 1 was not unique in this regard, similar studies were performed on a separate Pseudomonas isolate (strain 3). Again, no significant differences in pulmonary killing of mucoid and nonmucoid Pseudomonas were detected with this bacterial strain (Table  2) . Thus, in the untreated, immunologically intact animals, mucoid coating did not appear to selectively protect Pseudomonas from the normal defense mechanisms of phagocytosis and killing.
Since washing of mucoid Pseudomonas was carried out before lung challenges, the present analysis was based upon the assumption that mucoid strains were able to produce exopolysaccharide in vivo. Although direct morphological demonstration of mucoid material in vivo was not available in these studies, others have demonstrated this phenomenon (13) . It was also reassuring to find that Pseudomonas cultured from lungs infected with mucoid strains consistently displayed mucoid colonial morphology. Finally, to infect with mucoid organisms which might direct their metabolic efforts primarily toward exopolysaccharide production rather than maximal mitotic activity, organisms which were entering declining log phase were routinely used for these challenges. To ensure that different results would not occur with organisms harvested at mid-log growth phase, groups of six guinea pigs were challenged with equivalent inocula (1.6 x 108 CFU) of strain 1 (19, 22) . However, when groups of vaccinees were compared for intrapulmonary killing of mucoid versus nonmucoid Pseudomonas, no significant difference was seen at 6 h (56.0 ± 10, nonmucoid; 61.2 ± 13, mucoid), 24 h (19.2 ± 7, nomnucoid; 22.4 ± 13, mucoid), or 48 h (17.3 ± 5, nonmucoid; 5.0 ± 1.8, mucoid) after infection (mean values expressed as CFU x 103 per milliliter of lung homogenate, with five animals in each study group). Since increased pulmonary killing of Pseudomonas in vaccinated guinea pigs appears to be dependent upon specific opsonic antibodies (21) , the present findings suggest that mucoid coating did not block opsonic antibody activity in the lungs.
Likewise, a regimen of tobramycin sulfate, shown earlier to enhance killing of Pseudomonas in guinea pig lungs (23) , again offered increased killing in lung tissues when treated animals were compared with an untreated control group. As before, the control group included both mucoid-and nonmucoid-infected animals. After 6 h of infection, the mean values (CFU x 103 Pseudomonas per milliliter of lung homogenate) were 181.1 + 35 in controls and 79.0 + 13 in treated animals (P < 0.01, Student's t-test). When tobramycin-treated mucoid-and nonmucoid-infected groups were compared, however, there was no evidence that mucoid coating selectively prevented the normal intrapulmonary effectiveness of the antibiotic at 6 h (90.3 + 20, nonmucoid; 65.8 + 17, mucoid) or 24 h (25.9 ± 11, nonmucoid; 13.7 ± 6, mucoid) after infection (mean values expressed as CFU x 103 per milliliter of lung homogenate, with six animals in each study group).
DISCUSSION
The pathogenesis of lung disease in CF is complex and not fully understood (28) . It is clear, however, that in a large percentage of CF patients, chronic bronchitis with P. aeruginosa is associated with deteriorating lung function (4, 24, 25, 28) . A number of clinical observations have been reported which correlate more severe lung disease among CF patients with specific microbiological and immunological settings. These include isolation of the mucoid variety of P. aeruginosa from sputum (3, 11, 27) , high CLEARANCE OF MUCOID PSEUDOMONAS 447 sputa of CF patients, may confer a selective survival advantage in the CF lung by inhibiting normal pulmonary host defense mechanisms (9, 11, 13) . The present study has used an animal model, previously shown to be useful in studies of pulmonary host defense (18) (19) (20) (21) (22) (23) , in an attempt to demonstrate a selective defect in intrapulmonary killing of mucoid-coated P. aeruginosa.
A number of in vitro studies have been done to evaluate the influence of mucoid coating of Pseudomonas on bacterial susceptibility to phagocytic cells. These studies have produced conflicting data. Schwarzmann and Boring separated slime from a mucoid Pseudomonas isolated from the sputum of a CF patient and demonstrated an antiphagocytic property of this material when an excess of slime was mixed with mucoid Pseudomonas and polymorphonuclear leukocytes (26) . However, unless exogenous slime was added to these leukocyte-bacteria mixtures, no difference in phagocytosis of mucoid and nonmucoid Pseudomonas could be demonstrated. Antiserum, raised in rabbits by intravenous injections with a combination of slime and mucoid Pseudomonas, was able to reverse the antiphagocytic properties of exogenous Pseudomonas slime. Thus, it appeared that slime did not prevent the action of specific opsonic antibodies. In contrast, Baltimore and Mitchell recently reported that certain strains of mucoid Pseudomonas isolated from CF patients required greater amounts of antibody for effective opsonophagocytosis than did their nonmucoid revertants (1) . Attempts by these investigators to inhibit phagocytosis of nonmucoid Pseudomonas by the addition of exogenous slime to bacteria-leukocyte mixtures were unsuccessful, however. Additionally, a preopsonized mucoid Pseudomonas stained brightly for the presence of antibody coating when the indirect inmunofluorescence technique was used (1) . This is in contrast to similar studies by others (16) . Finally, it was reported by Govan and Fyfe that mucoid Pseudomonas isolates from CF sputa were more resistant to a variety of antibiotics, including tobramycin and carbenicillin (9) . Conversely, Thomassen and co-workers recently screened a large number of P. aeruginosa isolates from CF sputa for antibiotic susceptibility and found that mucoid strains were more susceptible than nonmucoid strains to tobramycin and carbenicillin (27) .
Many of these inconsistencies in the in vitro analysis of mucoid and nonmucoid Pseudomonas may relate to the variables of bacterial processing. The amount of mucoid coating will depend upon duration of growth as well as on the harvesting and washing procedures. Clearly, an in vivo system would offer an opportunity to mininmize the variables of in vitro analysis and would allow an evaluation of killing of mucoid Pseudomonas under more physiological conditions. Although such in vivo analyses are dependent upon the expression of mucoidy in the lung, recent morphological evidence exists to support this phenomenon (13) . One limitation in the present analysis was the lack ofmethodology to directly quantitate and compare exopolysaccharide capsules for mucoid and nonmucoid Pseudomonas in the lung tissues. A recently described technique for antibody-mediated stabilization of polysaccharide bacterial capsules (15) may provide a method for such direct morphological comparisons. It should also be noted that Pseudomonas grown in specialized media appear capable of producing unusually large amounts of exopolysaccharide (13) , and it is possible that organisms grown in such media might be better suited to in vivo studies. Since the original descriptions of mucoid Pseudomonas from CF lungs used conventional media, however, and since the biochemical relationship between highly specialized media and CF respiratory fluids is not established, we used conventional culture media for this study.
The difficulty in establishing an animal model to mimic the chronic Pseudomonas lung infection seen in CF patients is well known. Cash et al. recently incorporated P. aeruginosa into microscopic agar beads and instilled them into rat lungs (2) 
